Botensilimab
- Generic Name
- Botensilimab
- Drug Type
- Biotech
- CAS Number
- 2408310-37-0
- Unique Ingredient Identifier
- 1Z5YC3ME5N
- Background
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal AdenocarcinomaStage IV Colon Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Metastatic Colon AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage IV Colorectal Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: X-Ray Imaging
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05627635
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT05608044
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
🇷🇺Branch office of " Hadassah Medical Ltd", Moscow, Russian Federation
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT05529316
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Belgium
🇧🇷Oncosite - Centro de Pesquisa Clinica Em Oncologia, IjuÃ, Brazil
🇧🇷Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho, Jaú, Brazil
Study of AGEN1571 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05377528
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT04121676
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Roswell Park Comprehensive Cancer Care, Buffalo, New York, United States
🇺🇸Columbia University, New York, New York, United States
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
- Conditions
- Metastatic Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 65
- Registration Number
- NCT04028063
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
- Conditions
- Advanced CancerNon-small-cell Lung CancerOvarian CancerProstate CancerColorectal Cancer Without Liver MetastasesEndometrial CancerFibrolamellar CarcinomaAngiosarcoma
- Interventions
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 499
- Registration Number
- NCT03860272
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.